This segment focuses on the research, development, and commercialization of abuse-deterrent formulations for central nervous system (CNS) disorders. The primary focus is on developing and advancing ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. Research and development activities include clinical trials to evaluate the safety, efficacy, and abuse liability of ADAIR. The company utilizes advanced pharmaceutical technologies to create formulations that deter abuse while maintaining therapeutic efficacy. This segment addresses the significant patient need for safer and more effective treatments for ADHD and narcolepsy, with a focus on reducing the risk of misuse and diversion. Market positioning is centered on providing innovative solutions in the CNS therapeutic area, with a competitive advantage in abuse-deterrent technology. Future opportunities include expanding the product pipeline and securing regulatory approvals. Regulatory and clinical aspects involve navigating FDA approval processes and conducting clinical trials. Partnerships with manufacturing and distribution partners are crucial for commercialization.